 | |
| Clinical data | |
|---|---|
| Other names | 1BS-LSD; 1-(4-(Trimethylsilyl)benzoyl)-LSD |
| Pregnancy category |
|
| Dependence liability | Low |
| Addiction liability | None |
| Routes of administration | Oral [1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Liver (CYP450) |
| Duration of action | 7-12h |
| Excretion | Kidney |
| Chemical and physical data | |
| Formula | C30H36N3O2Si |
| Molar mass | 498.722 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
1SB-LSD, or 1BS-LSD, also known as 1-(4-(trimethylsilyl)benzoyl)-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). [1] It is thought to be a prodrug of LSD. [1] The drug was encountered online as a novel designer drug in September 2025. [1] 1SB-LSD has been sold in the form of blotter containing 165 μg per tab. [1] It is the derivative of 1Bz-LSD (SYN-L-018) in which there is a 4-trimethylsilyl group on the benzyl ring. [1] [2] 1SB-LSD is not an explicitly controlled substance in the United States [3] or in Canada. [4]
